Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00876317|
Recruitment Status : Terminated (Change in current areas of research interest of the collaborator)
First Posted : April 6, 2009
Last Update Posted : July 3, 2012
|Condition or disease||Intervention/treatment||Phase|
|Soft Tissue Injuries of the Shoulder Tenosynovitis and Bursitis Affecting the Shoulder||Drug: Etoricoxib 60 mg Drug: Etoricoxib 90 mg||Phase 3|
The main objective of this clinical trial is the assessment of the efficacy and safety of two single daily oral doses of etoricoxib 60 mg and 90 mg over a period of 14 days in the treatment of patients with acute soft tissue rheumatism affecting the shoulder. The study will be performed according to a randomised, double blind, double-dummy, and parallel-group.
In this study we will include 300 male or female out-patients, aged 18 years or above, with acute episodes of soft tissue rheumatism affecting the shoulder (less than 5 days). The main inclusion criteria will be: Shoulder pain of acute onset of non-traumatic origin, a history of painless unrestricted motion of the affected joint immediately before the acute attack, acute one-sided shoulder pain caused by soft tissue rheumatism, patient-assessed pain on active movement exceeding 50 mm on a 100-mm visual analogue scale and symptoms requiring therapy with NSAIDs.
The main exclusion criteria will be: Active or recurrent peptic (gastric or duodenal) ulcer, history of peptic ulcer or gastrointestinal bleeding, history of other bleeding disorders other than gastro-intestinal, concomitant treatment with anti-coagulants, lithium, other NSAIDs (including aspirin doses > 150 mg) or corticosteroids, local injections of steroids in the affecting shoulder (six months previous), presence of any form of crystal, destructive, infectious or inflammatory arthropathy, osteonecrosis, previous shoulder surgery in the affected side, adhesive capsulitis, cervical radiculopathy, severe renal, cardiac or hepatic failure, uncontrolled hypertension, pregnancy or breast feeding, confined to bed, planned hospital stays or surgical procedures during the trial, planned surgical intervention of the affected shoulder during the trial, alcohol or drug abuse and inability to comply with the protocol.
The study will have 4 Visits, at Day 1 (Visit 1), at Day 3 (Visit 2), at Day 7 (Visit 3) and at Day 14 (Visit 4). Potentially eligible patients will be screened at Visit 1. Patients found to be eligible will be allocated to one of the two treatments (etoricoxib 60 mg or 90 mg). Each patient will be treated for 14 days. Early termination of study on Visit 3 (Day 7) will be possible in case of complete resolution of the symptoms. All procedures of the study must be done after the patient sign the informed consent. An ultrasound and X-ray evaluation of the affected shoulder will be done on Day 1 and haematological and biochemistry laboratory evaluation will be done on Day 1 and at the end of treatment.
The primary end-point for efficacy will be the patient's assessment of pain on active movement on Day 3, the secondary end-point(s) for efficacy will be: Patient's assessment of pain on active movement during the last 24 hours, patient's assessment of pain at rest, the Brief Pain Inventory, final global assessment of efficacy by patient at the end of the treatment, final global assessment of efficacy by investigator at the end of the treatment, withdrawal due to inadequate efficacy, patient's status (change in painful condition at the end of therapy) and paracetamol consumption used as rescue medication. The secondary end-point(s) for safety and tolerability will be: Incidence and intensity of adverse events, final global assessment of tolerability by patient, final global assessment of tolerability by investigator, incidence of laboratory-related adverse events, and withdrawal of patients due to adverse events.
The results will be tabulated and the analysis of the data will perform in order to evaluate if the efficacy of the same doses of etoricoxib (60 mg and 90 mg) are equally effective for the treatment of acute shoulder pain syndrome due to soft tissue rheumatism affecting the shoulder.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||45 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Care Provider, Investigator)|
|Official Title:||Efficacy and Safety of Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder|
|Study Start Date :||November 2009|
|Primary Completion Date :||November 2010|
|Study Completion Date :||December 2010|
Active Comparator: 1
Etoricoxib 60 mg per oz for 14 days
Drug: Etoricoxib 60 mg
Etoricoxib 60 mg per oz per day for 14 days
Active Comparator: 2
Etoricoxib 90 mg per oz for 14 days
Drug: Etoricoxib 90 mg
Etoricoxib 90 mg per oz for 14 days
- Pain on active movement [ Time Frame: Day 3 ]
- Brief Pain Inventory [ Time Frame: Days 0, 3, 7 and 14 ]
- Global tolerability evaluation by the physician at the end of the study [ Time Frame: Day 14 ]
- Incidence and intensity of adverse events [ Time Frame: Days 3, 7 and 14 ]
- Global tolerability evaluation by the patient at the end of the study [ Time Frame: Day 14 ]
- Evaluation of pain at resting in the affecting shoulder the last 24 hours (VAS) [ Time Frame: Days 0, 3, 7 and 14 ]
- Pain on active movement [ Time Frame: Day 0, 7, 14 ]
- Patient's assessment of pain on active movement during the last 24 hours [ Time Frame: Day 0, 3, 7 and 14 ]
- Final global assessment of efficacy by patient at the end of the treatment [ Time Frame: Day 14 ]
- Final global assessment of efficacy by investigator at the end of the treatment [ Time Frame: Day 14 ]
- Withdrawal due to inadequate efficacy [ Time Frame: Day 14 ]
- Paracetamol consumption used as rescue medication [ Time Frame: Days 3, 7 and 14 ]
- Withdrawal of patients due to adverse events [ Time Frame: Days 3, 7 and 14 ]
- Additional visits to a physician due to adverse event [ Time Frame: Days 3, 7 and 14 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00876317
|Clínica Virgen Milagrosa|
|Lima, Peru, Lima 34|
|Principal Investigator:||Luis F Vidal, MD||Centro Diagnóstico de la Osteoporosis y Enfermedades Reumáticas|